TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Monoclonal antibodies (mAbs) Biosimilars Market Research Report 2023

Global Monoclonal antibodies (mAbs) Biosimilars Market Research Report 2023

  • Category:Life Sciences
  • Published on : 14 February 2023
  • Pages :87
  • Formats:
  • Report Code:SMR-7565916

Market Analysis and Insights: Global Monoclonal antibodies mAbs Biosimilars Market

The global Monoclonal antibodies mAbs Biosimilars market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Monoclonal antibodies mAbs Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Monoclonal antibodies mAbs Biosimilars market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Monoclonal antibodies mAbs Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Monoclonal antibodies mAbs Biosimilars market.

Global Monoclonal antibodies mAbs Biosimilars Scope and Market Size

Monoclonal antibodies (mAbs) Biosimilars market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Monoclonal antibodies (mAbs) Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2032.
Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Segment by Application
Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Monoclonal antibodies mAbs Biosimilars product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Monoclonal antibodies mAbs Biosimilars, with price, sales, revenue, and global market share of Monoclonal antibodies mAbs Biosimilars from 2019 to 2022.

Chapter 3, the Monoclonal antibodies mAbs Biosimilars competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Monoclonal antibodies mAbs Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Monoclonal antibodies mAbs Biosimilars market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Monoclonal antibodies mAbs Biosimilars.

Chapter 13, 14, and 15, to describe Monoclonal antibodies mAbs Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Monoclonal antibodies mAbs Biosimilars Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Erythropoietin (EPO)
1.2.3 Human Growth Hormone (HGH)
1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.5 Monoclonal Antibody (mAb)
1.2.6 Insulin
1.2.7 Interferon (IFN)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Anti-Cancer
1.3.3 Anti-Inflammatory/Autoimmune
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2018-2032)
2.2 Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Region
2.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Region (2018-2023)
2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2023-2032)
2.3 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics
2.3.1 Monoclonal antibodies (mAbs) Biosimilars Industry Trends
2.3.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
2.3.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
2.3.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue
3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2018-2023)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2018-2023)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2022
3.5 Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.6 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.7 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2018-2023)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2023-2032)
5 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2018-2023)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2018-2032)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2018-2032)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size (2018-2032)
8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023)
8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size (2018-2032)
9.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023)
9.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size (2018-2032)
10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023)
10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Biocon
11.1.1 Biocon Company Detail
11.1.2 Biocon Business Overview
11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
11.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.1.5 Biocon Recent Development
11.2 Celltrion
11.2.1 Celltrion Company Detail
11.2.2 Celltrion Business Overview
11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
11.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.2.5 Celltrion Recent Development
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Company Detail
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
11.3.4 Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.3.5 Dr. Reddy's Laboratories Recent Development
11.4 Hospira
11.4.1 Hospira Company Detail
11.4.2 Hospira Business Overview
11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
11.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.4.5 Hospira Recent Development
11.5 3SBio
11.5.1 3SBio Company Detail
11.5.2 3SBio Business Overview
11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
11.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.5.5 3SBio Recent Development
11.6 Accord Healthcare
11.6.1 Accord Healthcare Company Detail
11.6.2 Accord Healthcare Business Overview
11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
11.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.6.5 Accord Healthcare Recent Development
11.7 AET Biotech
11.7.1 AET Biotech Company Detail
11.7.2 AET Biotech Business Overview
11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.7.5 AET Biotech Recent Development
11.8 Allergan
11.8.1 Allergan Company Detail
11.8.2 Allergan Business Overview
11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
11.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.8.5 Allergan Recent Development
11.9 Amega Biotech
11.9.1 Amega Biotech Company Detail
11.9.2 Amega Biotech Business Overview
11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
11.9.5 Amega Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2032
Table 2. Key Players of Erythropoietin (EPO)
Table 3. Key Players of Human Growth Hormone (HGH)
Table 4. Key Players of Granulocyte- Colony Stimulating Factor (G-CSF)
Table 5. Key Players of Monoclonal Antibody (mAb)
Table 6. Key Players of Insulin
Table 7. Key Players of Interferon (IFN)
Table 8. Key Players of Others
Table 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2032
Table 10. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2032
Table 11. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2018-2023)
Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2023-2032) & (US$ Million)
Table 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2023-2032)
Table 15. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Table 16. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Table 17. Monoclonal antibodies (mAbs) Biosimilars Market Challenges
Table 18. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Table 19. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2018-2023) & (US$ Million)
Table 20. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2018-2023)
Table 21. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
Table 22. Ranking of Global Top Monoclonal antibodies (mAbs) Biosimilars Companies by Revenue (US$ Million) in 2022
Table 23. Global 5 Largest Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue (CR5 and HHI) & (2018-2023)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
Table 26. Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2018-2023) & (US$ Million)
Table 29. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2018-2023)
Table 30. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2023-2032) & (US$ Million)
Table 31. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2023-2032)
Table 32. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2018-2023) & (US$ Million)
Table 33. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2018-2023)
Table 34. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2023-2032) & (US$ Million)
Table 35. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2023-2032)
Table 36. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032) & (US$ Million)
Table 38. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032) & (US$ Million)
Table 40. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2023-2032) & (US$ Million)
Table 42. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032) & (US$ Million)
Table 44. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2023-2032) & (US$ Million)
Table 46. Biocon Company Detail
Table 47. Biocon Business Overview
Table 48. Biocon Monoclonal antibodies (mAbs) Biosimilars Product
Table 49. Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 50. Biocon Recent Development
Table 51. Celltrion Company Detail
Table 52. Celltrion Business Overview
Table 53. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product
Table 54. Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 55. Celltrion Recent Development
Table 56. Dr. Reddy's Laboratories Company Detail
Table 57. Dr. Reddy's Laboratories Business Overview
Table 58. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product
Table 59. Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 60. Dr. Reddy's Laboratories Recent Development
Table 61. Hospira Company Detail
Table 62. Hospira Business Overview
Table 63. Hospira Monoclonal antibodies (mAbs) Biosimilars Product
Table 64. Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 65. Hospira Recent Development
Table 66. 3SBio Company Detail
Table 67. 3SBio Business Overview
Table 68. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product
Table 69. 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 70. 3SBio Recent Development
Table 71. Accord Healthcare Company Detail
Table 72. Accord Healthcare Business Overview
Table 73. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product
Table 74. Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 75. Accord Healthcare Recent Development
Table 76. AET Biotech Company Detail
Table 77. AET Biotech Business Overview
Table 78. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 79. AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 80. AET Biotech Recent Development
Table 81. Allergan Company Detail
Table 82. Allergan Business Overview
Table 83. Allergan Monoclonal antibodies (mAbs) Biosimilars Product
Table 84. Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 85. Allergan Recent Development
Table 86. Amega Biotech Company Detail
Table 87. Amega Biotech Business Overview
Table 88. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 89. Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023) & (US$ Million)
Table 90. Amega Biotech Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type: 2022 VS 2032
Figure 2. Erythropoietin (EPO) Features
Figure 3. Human Growth Hormone (HGH) Features
Figure 4. Granulocyte- Colony Stimulating Factor (G-CSF) Features
Figure 5. Monoclonal Antibody (mAb) Features
Figure 6. Insulin Features
Figure 7. Interferon (IFN) Features
Figure 8. Others Features
Figure 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application in 2022 & 2032
Figure 10. Anti-Cancer Case Studies
Figure 11. Anti-Inflammatory/Autoimmune Case Studies
Figure 12. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered
Figure 13. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million), Year-over-Year: 2018-2032
Figure 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Size, (US$ Million), 2018 VS 2022 VS 2032
Figure 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Region: 2022 VS 2032
Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players in 2022
Figure 17. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2022
Figure 19. North America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 20. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2018-2032)
Figure 21. United States Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 22. Canada Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 23. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 24. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2018-2032)
Figure 25. Germany Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 26. France Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 27. U.K. Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 28. Italy Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 29. Russia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 30. Nordic Countries Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 31. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 32. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2018-2032)
Figure 33. China Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 34. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 35. South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 36. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 37. India Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 38. Australia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 39. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 40. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2018-2032)
Figure 41. Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 42. Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 43. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 44. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2018-2032)
Figure 45. Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 46. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 47. Biocon Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 48. Celltrion Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 49. Dr. Reddy's Laboratories Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 50. Hospira Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 51. 3SBio Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 52. Accord Healthcare Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 53. AET Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 54. Allergan Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 55. Amega Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed

Offer REPORT BUYING OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount